Skip to main content
SpringerLink
Log in

Colorectal Cancer Circulating Biomarkers

  • Reference work entry
Biomarkers in Cancer

Abstract

Circulating CRC markers might become useful tools for the massive screening of people since they satisfy a high degree of accuracy, noninvasiveness, reproducibility, and economy. Within circulating biomarkers, we will focus on the detection of autoantibodies in serum from cancer patients and their target tumor-associated antigens (TAAs). Although the sensitivity, specificity, and predictive value of individual TAAs present low scores, the combination of multiple TAAs shows improved values to discriminate between CRC patients and controls. In this review, we outline the methodologies used to identify circulating autoantibodies and their target proteins and discuss the relevance of CRC autoantibodies for diagnosis at, particularly, early stages. An overview of the reported biomarkers is given, showing the large complexity of the autoantibody response in cancer. Different strategies to improve CRC diagnostic tests by combining autoantibodies from different studies will be discussed. Association of autoantibodies to prognosis, recurrence, and the survival of patients will be introduced. We conclude that there is a great potential for the use of autoantibodies as diagnostic CRC biomarkers in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Abbreviations

CEA:

Carcinoembryonic antigen

CRC:

Colorectal cancer

EMT:

Epithelial to mesenchymal transition

HPLC:

High-performance liquid chromatography

MSI:

Microsatellite instability

NAPPA:

Nucleic acid programmable protein arrays

PTMs:

Posttranslational modifications

SEREX:

Serological analysis of recombinant cDNA expression libraries

SERPA:

Serological proteome analysis

TAA:

Tumor-associated antigen

References

  • Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res. 2005;4:1123–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Anderson KS, Ramachandran N, Wong J, et al. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res. 2008;7:1490–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Babel I, Barderas R, Diaz-Uriarte R, et al. Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol Cell Proteomics. 2009;8:2382–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Babel I, Barderas R, Diaz-Uriarte R, et al. Identification of MST1/STK4 and SULF1 proteins as autoantibody targets for the diagnosis of colorectal cancer by using phage microarrays. Mol Cell Proteomics. 2011;10:M110 001784.

    Article  PubMed  PubMed Central  Google Scholar 

  • Barderas R, Babel I, Casal JI. Colorectal cancer proteomics, molecular characterization and biomarker discovery. Proteomics Clin Appl. 2010;4:159–78.

    Article  CAS  PubMed  Google Scholar 

  • Barderas R, Babel I, Diaz-Uriarte R, et al. An optimized predictor panel for colorectal cancer diagnosis based on the combination of tumor-associated antigens obtained from protein and phage microarrays. J Proteomics. 2012;75:4647–55.

    Article  CAS  PubMed  Google Scholar 

  • Barderas R, Villar-Vazquez R, Fernandez-Acenero MJ, et al. Sporadic colon cancer murine models demonstrate the value of autoantibody detection for preclinical cancer diagnosis. Sci Rep. 2013;3:2938.

    Article  PubMed  PubMed Central  Google Scholar 

  • Bracci PM, Zhou M, Young S, et al. Serum autoantibodies to pancreatic cancer antigens as biomarkers of pancreatic cancer in a San Francisco Bay Area case–control study. Cancer. 2012;118:5384–94.

    Article  PubMed  PubMed Central  Google Scholar 

  • Bussow K, Cahill D, Nietfeld W, et al. A method for global protein expression and antibody screening on high-density filters of an arrayed cDNA library. Nucleic Acids Res. 1998;26:5007–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bussow K, Nordhoff E, Lubbert C, et al. A human cDNA library for high-throughput protein expression screening. Genomics. 2000;65:1–8.

    Article  CAS  PubMed  Google Scholar 

  • Carey TE, Takahashi T, Resnick LA, et al. Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A. 1976;73:3278–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Casal JI, Barderas R. Identification of cancer autoantigens in serum: toward diagnostic/prognostic testing? Mol Diagn Ther. 2010;14:149–54.

    Article  CAS  PubMed  Google Scholar 

  • Chang WJ, Wu LL, Cao FA, et al. Development of autoantibody signatures as biomarkers for early detection of colorectal carcinoma. Clin Cancer Res. 2011;17:5715–24.

    Article  CAS  PubMed  Google Scholar 

  • Chatterjee M, Mohapatra S, Ionan A, et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. 2006;66:1181–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chatterjee M, Dyson G, Levin NK, et al. Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence. Cancer Biomark. 2012;11:59–73.

    CAS  PubMed  Google Scholar 

  • Chen Y, Lin P, Qiu SM, et al. Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection. Int J Oncol. 2007;30:1137–44.

    CAS  PubMed  Google Scholar 

  • Chen JS, Kuo YB, Chou YP, et al. Detection of autoantibodies against Rabphilin-3A-like protein as a potential biomarker in patient’s sera of colorectal cancer. Clin Chim Acta. 2011;412:1417–22.

    Article  CAS  PubMed  Google Scholar 

  • Dippold WG, Lloyd KO, Li LT, et al. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A. 1980;77:6114–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dudas SP, Chatterjee M, Tainsky MA. Usage of cancer associated autoantibodies in the detection of disease. Cancer Biomark. 2010;6:257–70.

    PubMed  PubMed Central  Google Scholar 

  • Duffy MJ, van Dalen A, Haglund C, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43:1348–60.

    Article  CAS  PubMed  Google Scholar 

  • Fan CW, Chan CC, Chen KT, et al. Identification of SEC61 beta and its autoantibody as biomarkers for colorectal cancer. Clin Chim Acta. 2011;412:887–93.

    Article  CAS  PubMed  Google Scholar 

  • Festa F, Rollins SM, Vattem K, et al. Robust microarray production of freshly expressed proteins in a human milieu. Proteomics Clin Appl. 2013;7:372–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • He YJ, Wu YZ, Mou ZR, et al. Proteomics-based identification of HSP60 as a tumor-associated antigen in colorectal cancer. Proteomics Clin Appl. 2007;1:336–42.

    Article  CAS  PubMed  Google Scholar 

  • Hudson ME, Pozdnyakova I, Haines K, et al. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci U S A. 2007;104:17494–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ishikawa T, Fujita T, Suzuki Y, et al. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res. 2003;63:5564–72.

    CAS  PubMed  Google Scholar 

  • Jiang BH, Ren TT, Dong B, et al. Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients. Am J Pathol. 2010;177:1095–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kijanka G, Hector S, Kay EW, et al. Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer. Gut. 2010;59:69–78.

    Article  CAS  PubMed  Google Scholar 

  • Klade CS, Voss T, Krystek E, et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics. 2001;1:890–8.

    Article  CAS  PubMed  Google Scholar 

  • Kocer B, McKolanis J, Soran A. Humoral immune response to MUC5AC in patients with colorectal polyps and colorectal carcinoma. BMC Gastroenterol. 2006;6.

    Google Scholar 

  • Kronick MN. Creation of the whole human genome microarray. Expert Rev Proteomics. 2004;1:19–28.

    Article  CAS  PubMed  Google Scholar 

  • Kung LA, Snyder M. Proteome chips for whole-organism assays. Nat Rev Mol Cell Biol. 2006;7:617–22.

    Article  CAS  PubMed  Google Scholar 

  • Lam S, Boyle P, Healey GF, et al. Early CDT-lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila). 2011;4:1126–34.

    Article  Google Scholar 

  • Levin B, Brooks D, Smith RA, et al. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin. 2003;53:44–55.

    Article  PubMed  Google Scholar 

  • Line A, Slucka Z, Stengrevics A, et al. Characterisation of tumour-associated antigens in colon cancer. Cancer Immunol Immunother. 2002;51:574–82.

    Article  CAS  PubMed  Google Scholar 

  • Ling MM, Ricks C, Lea P. Multiplexing molecular diagnostics and immunoassays using emerging microarray technologies. Expert Rev Mol Diagn. 2007;7:87–98.

    Article  CAS  PubMed  Google Scholar 

  • Liotta LA, Espina V, Mehta AI, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell. 2003;3:317–25.

    Article  CAS  PubMed  Google Scholar 

  • Liu W, Wang P, Li Z, et al. Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer. Scand J Immunol. 2009;69:57–63.

    Article  CAS  PubMed  Google Scholar 

  • Liu W, Li Z, Xu W, et al. Humoral autoimmune response to IGF2 mRNA-binding protein (IMP2/p62) and its tissue-specific expression in colon cancer. Scand J Immunol. 2013;77:255–60.

    Article  CAS  PubMed  Google Scholar 

  • Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313–27.

    Article  CAS  PubMed  Google Scholar 

  • Lubin R, Schlichtholz B, Teillaud JL, et al. p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res. 1995;1:1463–9.

    CAS  PubMed  Google Scholar 

  • Mange A, Lacombe J, Bascoul-Mollevi C, et al. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer. Clin Cancer Res. 2012;18:1992–2000.

    Article  CAS  PubMed  Google Scholar 

  • Mintz PJ, Kim J, Do KA, et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol. 2003;21:57–63.

    Article  CAS  PubMed  Google Scholar 

  • Murphy MA, O’Connell DJ, O’Kane SL, et al. Epitope presentation is an important determinant of the utility of antigens identified from protein arrays in the development of autoantibody diagnostic assays. J Proteomics. 2012a;75:4668–75.

    Article  CAS  PubMed  Google Scholar 

  • Murphy MA, O’Leary JJ, Cahill DJ. Assessment of the humoral immune response to cancer. J Proteomics. 2012b;75:4573–9.

    Article  CAS  PubMed  Google Scholar 

  • Nam MJ, Madoz-Gurpide J, Wang H, et al. Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics. 2003;3:2108–15.

    Article  CAS  PubMed  Google Scholar 

  • O’Rourke DJ, DiJohnson DA, Caiazzo RJ, et al. Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen. Clin Chim Acta. 2012;413:561–7.

    Article  PubMed  Google Scholar 

  • Ochiai H, Ohishi T, Osumi K, et al. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Surg Today. 2012;42:164–8.

    Article  CAS  PubMed  Google Scholar 

  • Oishi Y, Yunomura S, Kawahashi Y, et al. Escherichia coli proteome chips for detecting protein-protein interactions. Proteomics. 2006;6:6433–6.

    Article  CAS  PubMed  Google Scholar 

  • Orenes-Pinero E, Barderas R, Rico D, et al. Serum and tissue profiling in bladder cancer combining protein and tissue arrays. J Proteome Res. 2010;9:164–73.

    Article  CAS  PubMed  Google Scholar 

  • Pallasch CP, Struss AK, Munnia A, et al. Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival. Int J Cancer. 2005;117:456–9.

    Article  CAS  PubMed  Google Scholar 

  • Pedersen JW, Blixt O, Bennett EP, et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer. 2011;128:1860–71.

    Article  CAS  PubMed  Google Scholar 

  • Pedersen JW, Gentry-Maharaj A, Fourkala EO, et al. Early detection of cancer in the general population: a blinded case–control study of p53 autoantibodies in colorectal cancer. Br J Cancer. 2013;108:107–14.

    Article  CAS  PubMed  Google Scholar 

  • Pedersen JW, Gentry-Maharaj A, Nostdal A, et al. Cancer associated auto-antibodies to MUC1 and MUC4 – A blinded case control study of colorectal cancer in UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Int J Cancer. 2014;134:2180–88.

    Google Scholar 

  • Pelaez-Garcia A, Barderas R, Torres S, et al. FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer. PLoS One. 2013;8:e63695.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054–61.

    Article  CAS  PubMed  Google Scholar 

  • Qiu J, Madoz-Gurpide J, Misek DE, et al. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res. 2004;3:261–7.

    Article  CAS  PubMed  Google Scholar 

  • Ramachandran N, Hainsworth E, Bhullar B, et al. Self-assembling protein microarrays. Science. 2004;305:86–90.

    Article  CAS  PubMed  Google Scholar 

  • Ran YL, Hu H, Zhou Z, et al. Profiling tumor-associated autoantibodies for the detection of colon cancer. Clin Cancer Res. 2008;14:2696–700.

    Article  CAS  PubMed  Google Scholar 

  • Reipert BM, Tanneberger S, Pannetta A, et al. Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer? Cancer Immunol Immunother. 2005;54:1038–42.

    Article  CAS  PubMed  Google Scholar 

  • Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A. 1995;92:11810–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Scanlan MJ, Chen YT, Williamson B, et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer. 1998;76:652–8.

    Article  CAS  PubMed  Google Scholar 

  • Scanlan MJ, Welt S, Gordon CM, et al. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res. 2002;62:4041–7.

    CAS  PubMed  Google Scholar 

  • Schmetzer O, Moldenhauer G, Riesenberg R, et al. Quality of recombinant protein determines the amount of autoreactivity detected against the tumor-associated epithelial cell adhesion molecule antigen: low frequency of antibodies against the natural protein. J Immunol. 2005;174:942–52.

    Article  CAS  PubMed  Google Scholar 

  • Shebzukhov YV, Koroleva EP, Khlgatian SV, et al. Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients. Int J Cancer. 2005;117:800–6.

    Article  CAS  PubMed  Google Scholar 

  • Song MH, Ha JC, Lee SM, et al. Identification of BCP-20 (FBXO39) as a cancer/testis antigen from colon cancer patients by SEREX. Biochem Biophys Res Commun. 2011;408:195–201.

    Article  CAS  PubMed  Google Scholar 

  • Soussi T. p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000;60:1777–88.

    CAS  PubMed  Google Scholar 

  • Syrigos KN, Charalampopoulos A, Pliarchopoulou K, et al. Prognostic significance of autoantibodies against tropomyosin in patients with colorectal adenocarcinoma. Hybridoma. 1999;18:543–6.

    Article  CAS  PubMed  Google Scholar 

  • Syrigos KN, Charalambopoulos A, Pliarchopoulou K, et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 2000;20:4351–3.

    CAS  PubMed  Google Scholar 

  • Takulapalli BR, Qiu J, Magee DM, et al. High density diffusion-free nanowell arrays. J Proteome Res. 2012;11:4382–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tang RP, Ko MC, Wang JY, et al. Humoral response to P53 in human colorectal tumors: a prospective study of 1,209 patients. Int J Cancer. 2001;94:859–63.

    Article  CAS  PubMed  Google Scholar 

  • Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006;116:271–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wandall HH, Blixt O, Tarp MA, et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res. 2010;70:1306–13.

    Article  CAS  PubMed  Google Scholar 

  • Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med. 2005;353:1224–35.

    Article  CAS  PubMed  Google Scholar 

  • Zhu H, Snyder M. Protein arrays and microarrays. Curr Opin Chem Biol. 2001;5:40–5.

    Article  CAS  PubMed  Google Scholar 

  • Zhu H, Bilgin M, Bangham R, et al. Global analysis of protein activities using proteome chips. Science. 2001;293:2101–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biochemistry and Molecular Biology I Department, Facultad de Ciencias Químicas, Universidad Complutense de Madrid, Madrid, Spain

    Rodrigo Barderas

  2. Department of Cellular and Molecular Medicine, Functional Proteomics Laboratory, Centro de Investigaciones Biológicas (CSIC), Madrid, Spain

    Roi Villar-Vázquez & J. Ignacio Casal

Authors
  1. Rodrigo Barderas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roi Villar-Vázquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Ignacio Casal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Ignacio Casal .

Editor information

Editors and Affiliations

  1. Faculty of Life Sciences & Medicine King’s College London, Department of Nutrition and Dietetics Division of Diabetes & Nutritional Scien, London, United Kingdom

    Victor R. Preedy

  2. Faculty of Science & Technology, Department of Biomedical Sciences, University of Westminster, London, United Kingdom

    Vinood B. Patel

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media Dordrecht

About this entry

Cite this entry

Barderas, R., Villar-Vázquez, R., Casal, J.I. (2015). Colorectal Cancer Circulating Biomarkers. In: Preedy, V., Patel, V. (eds) Biomarkers in Cancer. Biomarkers in Disease: Methods, Discoveries and Applications. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7681-4_29

Download citation

Publish with us

Policies and ethics

Search

Navigation